Based upon its well-regarded expertise on development of immunotherapeutics, STCube is set to conduct a joint research project through which the company will have access to infrastructures offered by Georgetown University

STCube is set to initiate a collaboration with Diviner Therapeutics in the U.S for development of novel immunotherapeutic drugs.

STCube reported on the 31st that it entered into a contract with U.S.-based Diviner Therapeutics which will enable multi-angled collaborations between the two companies in developing novel immunotherapeutic drugs. 

This contract enables Diviner Therapeutics to accelerate its antibody development utilizing STCube’s proprietary antibody screening and production technology.

Following the previous license out of its PD-L1 antibodies in China and Taiwan, STCube was once again recognized for its expertise on the development of novel immunotherapeutics. Based on this newly initiated collaboration, STCube can expect to diversify and expand the scope of the immunotherapeutic candidates in its pipelines.

Doctor Stephen W Byers, a co-founder of Diviner Therapeutics, has accumulated substantial experience and know-hows while conducting research on novel immunotherapy targets as a long-time Professor of Oncology at Georgetown University.

STCube is accelerating the development of therapeutic antibodies based on Diviner’s expertise on certain immunotherapeutic targets using its proprietary antibody development platform. Particularly, some targets newly identified in this program are thought to be relevant not only for cancer but also for immunological disorders such as arthritis, and thus, the resulting drugs are likely to have therapeutic effects on a plurality of disorders.

One of the company officials stated: “STCube is in a great position to further accelerate the development of therapeutic antibodies with competitive edge through this collaboration since the company, in addition to securing novel therapeutic candidates from Diviner Therapeutics, laid out a foundation to utilize the state-of-the-art research facilities and resources available at Georgetown University."

He also added: “Efforts are put forth into investigation of various novel drug candidates with potentials and therefore into diversification of pipeline candicates. The current collaboration project will further contribute to our quest for novel immunotherapeutics with competitive edge." <End>